Novartis AG Common Stock (NY:NVS)

139.71 -1.29 (-0.91%)

Delayed Quote Updated: 11:06 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

59 60 Next >

Hepatocellular Carcinoma Market and Epidemiology 2032: Treatment Therapies, FDA Approvals, Companies and Market Forecasting by DelveInsight | AbbVie, Bayer, Novartis, Bristol-Myers Squibb, Takeda

June 14, 2023

Via AB Newswire

Nasopharyngeal Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Incyte, BeiGene, Klus Pharma, Merck, Roche, Novartis, Akeso Pharma

June 14, 2023

Via AB Newswire

Lupus Nephritis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Novartis, RemeGen, Roche, Annexon, Argenx, AstraZeneca, Aurinia

June 14, 2023

Via AB Newswire

Cystic Fibrosis Pipeline, Clinical Trials, and Key Companies|Companies – Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma

June 13, 2023

Via AB Newswire

Health Care Company Novartis Announces Merger With Chinook Therapeutics ↗

June 12, 2023

Via Benzinga

Is Novartis a Good Stock to Buy Right Now? ↗

June 07, 2023

The multinational pharma giant excels as an income play.

Via The Motley Fool

Looking At Novartis's Recent Unusual Options Activity ↗

June 01, 2023

Via Benzinga

Ophthalmoplegia Market expected to rise | Companies – Abbott, Novartis AG, ZEISS International, Valeant Pharmaceuticals International, ALLERGAN, Johnson & Johnson, expected to drive market

June 13, 2023

Via AB Newswire

KRAS Inhibitors Market to Witness Growth by 2032, Estimates DelveInsight | Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio

June 13, 2023

Via AB Newswire

Novartis Stock Screams Value After Chinook Therapeutics Buyout

June 13, 2023

Following a buyout of Chinook Therapeutics, Novartis slipped less than 1%. This speaks to the growth potential of Chinook and ongoing value of Novartis stock.

Via MarketBeat

IgA Nephropathy Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Alnylam, RemeGen, Novartis, Visterra/ Otsuka, Vera Therapeutics, Omeros Corp.

June 13, 2023

Via AB Newswire

KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook ↗

June 12, 2023

Chinook Therapeutics is about to be acquired by Novartis. News of this deal hasn't stopped Muddy Waters from betting against KDNY stock.

Via InvestorPlace

Bone Neoplasms Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies – Amgen, Novartis, Roche, Merck, Luye Pharma, Bayer, Pfizer.

June 12, 2023

Via AB Newswire

Opioid-Induced Constipation Market expected to rise | Companies – Cosmo Pharmaceuticals, Shionogi & Co., Merck & Co, Novartis AG, AstraZeneca plc, Bausch Health Companies, expected to boost the market

June 12, 2023

Via AB Newswire

Food Allergy Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Alladapt, Regeneron, InnoUp Farma, Novartis, Genentech, DBV Technologies

June 12, 2023

Via AB Newswire

Chinook Therapeutics Launches Almost 60% On Novartis' $3.5 Billion Takeover ↗

June 12, 2023

Novartis will pay $3.5 billion to buy the kidney disease-focused biotech company.

Via Investor's Business Daily

XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust ↗

June 12, 2023

Find out more about two big winners Monday morning.

Via The Motley Fool

2022 R&D Spending and Intensity Benchmarks

June 12, 2023

VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D...

Via PRLog

Topics Supply Chain

Broadcom Might Receive European Approval For $61B VMware Deal, UBS Closes Credit Suisse Takeover, Illumina CEO Steps Down Amid Activist Investor Carl Icahn's Pressure: Today's Top Stories ↗

June 12, 2023

Reuters Broadcom Most Likely To Receive EU Approval For $61B VMware Merger

Via Benzinga

Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today? ↗

June 12, 2023

Chinook Therapeutics (KDNY) stock is rocketing higher on Monday after the company announced it's being acquired by Novartis AG (NVS).

Via InvestorPlace

Hidradenitis Suppurativa Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | InflaRx, Novartis, ChemoCentryx, AnaptysBio, AbbVie, UCB Biopharma

June 12, 2023

Via AB Newswire

Exploring Novel Approaches to Diabetic Retinopathy Pipeline and Clinical Trials (2023) | Companies – Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular , Bayer, and Others

June 12, 2023

Via AB Newswire

Breakthrough Therapies and Potential Targets for Complement 3 Glomerulopathy Pipeline Analysis (2023) | Companies – ChemoCentryx, Novartis Pharma, Omeros Corporation, Apellis Pharma, and others

June 12, 2023

Via AB Newswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

June 12, 2023

We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!

Via InvestorPlace

Why Are Chinook Therapeutics Shares Trading Higher Today ↗

June 12, 2023

Novartis AG (NYSE: NVS) has agreed to acquire Chinook Therapeutics Inc (NASDAQ: KDNY) for $40 per share in cash,

Via Benzinga

Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low ↗

June 12, 2023

Via Benzinga

Amazon Considers Launching Ad-Supported Prime Video Tier, Google & Microsoft Face Backlash For Ad Inclusion In AI Trials, Airbus Records One-Third Jump In May Deliveries: Today's Top Stories ↗

June 08, 2023

Wall Street Journal

Via Benzinga

Novartis' Sandoz Foresees Rapid Growth Post Spin-Off in Generics Market Amid Upcoming Patent Expirations ↗

June 08, 2023

Novartis AG's (NYSE: NVS) generics unit Sandoz tells investors it can add $3 billion in annual sales over the next five years from launching new products after it spins out of its

Via Benzinga

Veterinary Healthcare Product Market to See Huge Growth : Pfizer, Merck, Johnson & Johnson

June 06, 2023

Stay up-to-date with Veterinary Healthcare Product Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application

May 30, 2023

Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin

Via MarketBeat

Topics Death

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.